Literature DB >> 32158915

A master regulator of cholesterol biosynthesis constitutes a therapeutic liability of triple negative breast cancer.

Demin Cai1, Xiong Zhang1, Hong-Wu Chen1.   

Abstract

Lipid and cholesterol reprogramming are often observed in specific cancer subtypes. We find that triple-negative breast cancers (TNBCs), but not estrogen receptor-positive (ER+) ones, adopt nuclear receptor RAR-related orphan receptor γ (RORγ) as their new master activator of cholesterol biosynthesis program. Its dominant role over sterol regulatory element-binding protein 2 (SREBP2) renders TNBC highly vulnerable to RORγ inhibitors alone or in combination with statins.
© 2020 Taylor & Francis Group, LLC.

Entities:  

Keywords:  ER-positive breast cancer; RORγ; SREBP2; TNBC; cholesterol homeostasis; chromatin; statins; therapy

Year:  2020        PMID： 32158915      PMCID： PMC7051132          DOI： 10.1080/23723556.2019.1701362

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  8 in total

Review 1.  The interplay between cell signalling and the mevalonate pathway in cancer.

Authors:  Peter J Mullen; Rosemary Yu; Joseph Longo; Michael C Archer; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2016-08-26       Impact factor: 60.716

Review 2.  REV-ERB and ROR nuclear receptors as drug targets.

Authors:  Douglas J Kojetin; Thomas P Burris
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

3.  Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.

Authors:  Olöf Bjarnadottir; Quinci Romero; Pär-Ola Bendahl; Karin Jirström; Lisa Rydén; Niklas Loman; Mathias Uhlén; Henrik Johannesson; Carsten Rose; Dorthe Grabau; Signe Borgquist
Journal:  Breast Cancer Res Treat       Date:  2013-03-08       Impact factor: 4.872

4.  Identification of natural RORγ ligands that regulate the development of lymphoid cells.

Authors:  Fabio R Santori; Pengxiang Huang; Serge A van de Pavert; Eugene F Douglass; David J Leaver; Brad A Haubrich; Rok Keber; Gregor Lorbek; Tanja Konijn; Brittany N Rosales; Damjana Rozman; Simon Horvat; Alain Rahier; Reina E Mebius; Fraydoon Rastinejad; W David Nes; Dan R Littman
Journal:  Cell Metab       Date:  2015-02-03       Impact factor: 27.287

5.  IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.

Authors:  Kelly Kersten; Chris W Doornebal; Seth B Coffelt; Jorieke Weiden; Kim Vrijland; Cheei-Sing Hau; Niels J M Verstegen; Metamia Ciampricotti; Lukas J A C Hawinkels; Jos Jonkers; Karin E de Visser
Journal:  Nature       Date:  2015-03-30       Impact factor: 49.962

6.  ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.

Authors:  Junjian Wang; June X Zou; Xiaoqian Xue; Demin Cai; Yan Zhang; Zhijian Duan; Qiuping Xiang; Joy C Yang; Maggie C Louie; Alexander D Borowsky; Allen C Gao; Christopher P Evans; Kit S Lam; Jianzhen Xu; Hsing-Jien Kung; Ronald M Evans; Yong Xu; Hong-Wu Chen
Journal:  Nat Med       Date:  2016-03-28       Impact factor: 53.440

7.  RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype.

Authors:  Demin Cai; Junjian Wang; Bei Gao; Jin Li; Feng Wu; June X Zou; Jianzhen Xu; Yuqian Jiang; Hongye Zou; Zenghong Huang; Alexander D Borowsky; Richard J Bold; Primo N Lara; Jian Jian Li; Xinbin Chen; Kit S Lam; Ka-Fai To; Hsing-Jien Kung; Oliver Fiehn; Ruqian Zhao; Ronald M Evans; Hong-Wu Chen
Journal:  Nat Commun       Date:  2019-10-11       Impact factor: 14.919

Review 8.  Statin drugs to reduce breast cancer recurrence and mortality.

Authors:  Colin H Beckwitt; Adam Brufsky; Zoltán N Oltvai; Alan Wells
Journal:  Breast Cancer Res       Date:  2018-11-20       Impact factor: 6.466
  8 in total
  5 in total

Review 1.  Advances in Analyzing the Breast Cancer Lipidome and Its Relevance to Disease Progression and Treatment.

Authors:  Ashley V Ward; Steven M Anderson; Carol A Sartorius
Journal:  J Mammary Gland Biol Neoplasia       Date:  2021-12-16       Impact factor: 2.673

2.  Conformational Changes of RORγ During Response Element Recognition and Coregulator Engagement.

Authors:  Timothy S Strutzenberg; Yingmin Zhu; Scott J Novick; Ruben D Garcia-Ordonez; Christelle Doebelin; Yuanjun He; Mi Ra Chang; Theodore M Kamenecka; Dean P Edwards; Patrick R Griffin
Journal:  J Mol Biol       Date:  2021-09-20       Impact factor: 5.469

Review 3.  Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer.

Authors:  Karan Mediratta; Sara El-Sahli; Vanessa D'Costa; Lisheng Wang
Journal:  Cancers (Basel)       Date:  2020-11-26       Impact factor: 6.639

4.  Genetic co-expression networks contribute to creating predictive model and exploring novel biomarkers for the prognosis of breast cancer.

Authors:  Yuan-Kuei Li; Huan-Ming Hsu; Meng-Chiung Lin; Chi-Wen Chang; Chi-Ming Chu; Yu-Jia Chang; Jyh-Cherng Yu; Chien-Ting Chen; Chen-En Jian; Chien-An Sun; Kang-Hua Chen; Ming-Hao Kuo; Chia-Shiang Cheng; Ya-Ting Chang; Yi-Syuan Wu; Hao-Yi Wu; Ya-Ting Yang; Chen Lin; Hung-Che Lin; Je-Ming Hu; Yu-Tien Chang
Journal:  Sci Rep       Date:  2021-03-31       Impact factor: 4.379

Review 5.  Nuclear Receptor RORα/γ: Exciting Modulators in Metabolic Syndrome and Related Disorders.

Authors:  Haotian Gu; Ping Hu; Yahui Zhao; Yaya Liu; Yi-Ting Wang; Abdelkareem A Ahmed; Hao-Yu Liu; Demin Cai
Journal:  Front Nutr       Date:  2022-06-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.